Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Emerald Health Pharmaceuticals has signed Lonza to make a synthetic derivative of cannabidiol it is developing to treat multiple sclerosis and systemic scleroderma. Under the contract, Lonza will synthesize the active pharmaceutical ingredient (API), VCE-004.8, and finished liquid-filled hard and soft-gel capsules. Lonza will make the API in Nansha, China; hard capsules in Edinburgh, Scotland; and soft gels in Ploermel, France. The agreement allows for further commercialization of novel cannabinoids.
This article has been sent to the following recipient: